Unfortunately, war is the daily media lead. We get the numbers of dead and injured for each conflict. You might consider those just injured as ‘lucky’ if you’re like me. Au contraire. Familiar issues are traumatic brain and spine injuries. Alongside lost limbs and wounds caused by bomb debris and emotional symptoms such as PTSD and depression that may persist for years, sometimes a lifetime. (Xaigham.com)
For life-saving technologies, war has unfortunately become a growth sector. I take no pleasure in saying that.
A sudden, traumatic blow to the spine (tSCI) can fracture, dislocate, crush or compress one or more of the vertebrae. A gunshot or knife wound that penetrates and cuts the spinal cord also can cause a spinal cord injury. Additional damage usually occurs over days or weeks.
The global Spinal Cord Trauma Treatment market was valued at US$ 2458.9 million in 2022 and is projected to reach US$ 3009.4 million by 2029, at a CAGR of 2.9% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The current Middle East conflict was not included. Unfortunately, those projected growth numbers could rise significantly.
While I am using the wars and conflicts as examples of the growth of the traumatic injury market, it was already significant and this is just the US.
The question arises: how is this issue addressed? There are myriad companies, large and small, looking for answers.
TORONTO and HAIFA, Israel, Jan. 05, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries.
How does it work? Stay with me; it’s pretty straightforward.
Part One: Active Ingredients
Exosomes: Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in the body, secreted by cells. Can be administered non-invasively, intranasally
Part Two: Delivery
ExoTherapy: Exosomes, loaded with therapeutic molecules, cross the blood-brain barrier and reach cells and tissues for regeneration, rewiring and recovery.
Part Three: Effect
SiRNA-PTEN: The suggested PTEN inhibition-based therapeutic targets are nerve growth and regeneration after injury or damage, treatment of cardiac ischemia/reperfusion and associated disease, wound repair, and infertility.
The goal is to reverse this traumatic brain trauma as well as develop other health issues such as depression—no small accomplishment. The US FDA has granted NRX Orphan Drug Status.
The Orphan Drug Designation program provides orphan status to drugs and biologics for rare diseases that meet specific criteria. Orphan drug designation provides incentives, including:
“Orphan-drug designation is expected to streamline our go-to-market, shorten our regulatory process, save the Company millions of dollars, and provide valuable market exclusivity. We appreciate the formal recognition of the potential impact of our therapy on the lives of patients suffering from acute spinal cord injuries,” said Dr. Shaltiel, CEO of NurExone Biologic, Ltd.
The Company also holds an exclusive worldwide license from Technion and Tel Aviv University for developing and commercializing the technology.
This technology is not only promising but appears well destined for success. In their totality, the current NRX out-front therapies could bring much relief to those seriously ‘injured’ patients who live with chronic pain and myriad challenges daily.
NurExome is a cutting-edge medical technology company. While trading has been modest, it paints a positive investment picture for the previously reasons stated. Will it pop tomorrow? No. That I can guarantee.
A savvy plan would to be to approach as a dollar-cost average investment. The deeper you dig, the more potential will become apparent.
Note Hyperlinks below.
Stock stats Jan 5 2024 | |
52 Week Range | 0.1000 0.4200 |
Volume | 7,000 |
Avg. Volume | 4,511 |
Market Cap | 14.475M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1100 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.01 |
In-depth Corporate Presentation Litchfield Research |
November 28, 2022
Marc ZERBOLA CHALLANDE
BioLife Sciences (OTC: BLFE) is a company that develops, licenses, and distributes antibacterial products. The company offers disinfecting wipes, UV sterilization technology, electrostatic disinfection services, antimicrobial textiles, and touchless vending/marketplace products. The company announced in late October that it partnered with Work In Motion to develop and distribute its custom-infused bamboo gardening gloves for international distribution through its extensive wholesale and distribution network. There is a lot of significant upside for the company that will be up-listing to the Over-the-Counter Quotation Bureau exchange (“OTCQB”)!
BioLife Sciences (OTC: BLFE) provides a broad range of services, including antimicrobial copper-infused textiles. Copper is a naturally-occurring metal that humanity has utilized since the early days. It has produced weapons, tools, currency, and jewelry. Additionally, copper was long-touted in India for its health benefits long before scientists began understanding microbes and viruses. In ancient Egypt, copper was used to purify water and prevent infections. This material is designed to inhibit virus & bacteria reproduction and cross-contamination before it starts. In other words, it will stop the spread before it starts. Copper-infused textiles were proven to prevent virus transmission from people who encounter the virus. The positive side is it fights against COVID-19 and other diseases, including MSRA and Ebola.
Additionally, the copper remains practical and durable even after repeated washes. BioLife also provides antimicrobial copper air filters. These air filters clean the air and release copper ions to protect against bacteria and germs circulating in enclosed rooms and buildings. It provides continuous protection for up to 30 days. Mid-November, the company announced its Q1 2023 slated release of its copper-infused fabric pot prototype. The BioLife fabric pot prototype has been in development for over a year, with the stated goal of providing a new alternative to gardening consumers who wish to grow plants with environmentally sustainable plant pots instead of the industry’s current offerings, which include plastic pots, terra cotta pots, glazed ceramic pots.
In late August, BioLife Sciences announced it would expand its product offerings in the orthomolecular medicine and natural health markets, focusing on hemp products. Moving to the hemp and cannabis sectors is a wise decision because these sectors gain more interest, and worldwide legislation is being eased. The company will continue focusing on throat and cough syrups infused with cannabinoids, cannabinoid-infused teas, and CBD energy shots. The company doesn’t just focus on humans but on pets as well. Indeed BioLife will focus on pet products infused with cannabinoids that offer wellness support for cats and dogs.
“Some view this market as already being over-saturated. However, at BioLife, we are confident that this sector will continue to grow in the coming years, and consumers as a whole are moving towards more holistic approaches such as CBD, CBG, and CBN. Consumers are continuing to become more aware of the benefits of CBD, and other cannabinoids, for not just humans, but for pets too.”
Nika Jaksic, COO
Among the new products, the company will focus on the following:
Hemp-Infused Throat and Cough Syrups: they will focus on natural sleep aids paired with flavor profiles that will absorb a higher bioavailability of the cannabinoids due to the use of water-soluble cannabinoids. It will include a mixture of medicinal herbs infused with CBG, CBN, CBD, CBGa, CBNa, CBDa, and additional cannabinoids, flavonoids, and terpenes. It will allow more effective treatment with improved results. Cannabinoid-Infused Energy Shots: those will be available for dogs and cats. It will be a full-spectrum supercritical CO2 extracted USDA organic CBD oil available in different strengths.
Moreover, peanut butter dog treats will be available with CBD for daytime snacks and CBN and CBG for evening snacks. And last but not least, cannabinoid-Infused Energy Shots. They are energy drink formulations infused with cannabinoids packed with vitamins to help consumers get through the day. Energy Drinks will be sugar-free and manufactured with the highest-quality ingredients.
Diving into the cannabinoid market is important regarding the market’s potential. In the US, the sector was worth USD $14.6B in 2021 and will witness a CAGR of 16.2% until 2030 to reach USD $60.4B. As stated above, the ease in legislation and the momentum growth for using cannabinoids for different medical conditions resulted in more substantial market adoption—the number of consumers rose, and the awareness concerning cannabis and cannabinoid products. Furthermore, the rising demand for minor and significant cannabinoids and positive research claiming their benefits in various health conditions have helped boost awareness about cannabinoid use. A growing study investigating the impact of cannabinoids on conditions such as epilepsy, cancer, chronic pain, arthritis, metabolic issues, and neurological disorders further bolstered growth. According to Life Beyond Numbers, 42% of the consumers using CBD stopped using traditional medications and preferred CBD products. In the US, the growing demand for cannabinoid products and increasing sales of cannabinoid products are yet another factor supporting the growth. The growth can be signified by increased retail sales, online sales, and internet searches for cannabis and related products. For instance, as per a 2019 research provided by Jama Network, web searches for CBD increased from 125.9% from 2016 to 2017 to 160.4% from 2017 to 2018.
BioLife Sciences (OTC: BLFE) is at the early stage of earning substantial revenue. The company’s market cap is significantly low because the company’s products are still in development, but 2023 should be very prolific. The stock price is meager, but investors should be more interested every time BioLife Sciences provides updates about new products, wholesale distribution, or subsequent revenues.
Marc has been involved in the Stock Market Media Industry for the last +4 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website. He then contributed to building Guerilla Capital, a Capital Markets company and FirstPhase Media where he was head of research. At10xAlerts, he writes articles and conducts interviews on many sectors, including technology, metals & mining markets.
©2024 10xAlerts